Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지
DOI QR코드

DOI QR Code

Down-Regulation of Survivin by Nemadipine-A Sensitizes Cancer Cells to TRAIL-Induced Apoptosis

  • Park, Seong Ho (Ilsong Institute for Life Science, Hallym University) ;
  • Park, So Jung (Graduate School of East-West Medical Science, Kyung Hee University) ;
  • Kim, Joo-Oh (Graduate School of East-West Medical Science, Kyung Hee University) ;
  • Shin, Ji Hyun (Graduate School of East-West Medical Science, Kyung Hee University) ;
  • Kim, Eun Sung (Graduate School of East-West Medical Science, Kyung Hee University) ;
  • Jo, Yoon Kyung (Graduate School of East-West Medical Science, Kyung Hee University) ;
  • Kim, Jae-Sung (Division of Radiation Cancer Research, Korea Institute of Radiological and Medical Science) ;
  • Park, So Jung (Asan Institute for Life Science, Asan Medical Center) ;
  • Jin, Dong-Hoon (Asan Institute for Life Science, Asan Medical Center) ;
  • Hwang, Jung Jin (Asan Institute for Life Science, Asan Medical Center) ;
  • Lee, Seung Jin (Asan Institute for Life Science, Asan Medical Center) ;
  • Jeong, Seong-Yun (Asan Institute for Life Science, Asan Medical Center) ;
  • Lee, Chaeyoung (Department of Bioinformatics and Life Science, Soongsil University) ;
  • Kim, InKi (Asan Institute for Life Science, Asan Medical Center) ;
  • Cho, Dong-Hyung (Graduate School of East-West Medical Science, Kyung Hee University)
  • Received : 2012.11.09
  • Accepted : 2012.11.28
  • Published : 2013.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

The tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the tumor necrosis factor family of cytokines. TRAIL selectively induces apoptotic cell death in various tumors and cancer cells, but it has little or no toxicity in normal cells. Agonism of TRAIL receptors has been considered to be a valuable cancer-therapeutic strategy. However, more than 85% of primary tumors are resistant to TRAIL, emphasizing the importance of investigating how to overcome TRAIL resistance. In this report, we have found that nemadipine-A, a cell-permeable L-type calcium channel inhibitor, sensitizes TRAIL-resistant cancer cells to this ligand. Combination treatments using TRAIL with nemadipine-A synergistically induced both the caspase cascade and apoptotic cell death, which were blocked by a pan caspase inhibitor (zVAD) but not by autophagy or a necrosis inhibitor. We further found that nemadipine-A, either alone or in combination with TRAIL, notably reduced the expression of survivin, an inhibitor of the apoptosis protein (IAP) family of proteins. Depletion of survivin by small RNA interference (siRNA) resulted in increased cell death and caspase activation by TRAIL treatment. These results suggest that nemadipine-A potentiates TRAIL-induced apoptosis by down-regulation of survivin expression in TRAIL resistant cells. Thus, combination of TRAIL with nemadipine-A may serve a new therapeutic scheme for the treatment of TRAIL resistant cancer cells, suggesting that a detailed study of this combination would be useful.

Keywords

References

  1. Abdulghani, J. and El-Deiry, W. S. (2010) TRAIL receptor signaling and therapeutics. Expert Opin. Ther. Targets 14, 1091-1108. https://doi.org/10.1517/14728222.2010.519701
  2. Altieri, D. C. (2010) Survivin and IAP proteins in cell-death mechanisms. Biochem. J. 430, 199-205. https://doi.org/10.1042/BJ20100814
  3. Ammann, J. U., Haag, C., Kasperczyk, H., Debatin, K. M. and Fulda, S. (2009) Sensitization of neuroblastoma cells for TRAIL-induced apoptosis by NF-kappaB inhibition. Int. J. Cancer 124, 1301-1311. https://doi.org/10.1002/ijc.24068
  4. Bellail, A. C., Qi, L., Mulligan, P., Chhabra, V. and Hao, C. (2009) TRAIL agonists on clinical trials for cancer therapy; the promises and the challenges. Rev. Recent Clin. Trials 4, 34-41. https://doi.org/10.2174/157488709787047530
  5. Cho, D. H., Jo, Y. K., Hwang, J. J., Lee, Y. M., Roh, S. A. and Kim, J. C. (2009) Caspase-mediated cleavage of ATG6/Beclin-1 links apoptosis to autophagy in HeLa cells. Cancer Lett. 274, 95-100. https://doi.org/10.1016/j.canlet.2008.09.004
  6. Frokjaer-Jensen, C., Kindt, K. S., Kerr, R. A., Suzuki, H., Melnik-Martinez, K., Gerstbreih, B., Driscol, M. and Schafer, W. R. (2006) Effects of voltage-gated calcium channel subunit genes on calcium influx in cultured C. elegans mechanosensory neurons. J. Neurobiol. 66, 1125-1139. https://doi.org/10.1002/neu.20261
  7. Hanahan, D. and Weinberg, R. A. (2000) The hallmarks of cancer. Cell 100, 57-70. https://doi.org/10.1016/S0092-8674(00)81683-9
  8. Hou, W., Han, J., Lu, C., Goldstein, L. A. and Rabinowich, H. (2008) Enhancement of tumor-TRAIL susceptibility by modulation of autophagy. Autophagy 4, 940-943. https://doi.org/10.4161/auto.6769
  9. Hui, K., Kwok, T. C., Kostelecki, W., Leen, J., Roy, P. J. and Feng, Z. P. (2009) Differential sensitivities of CaV1.2 IIS5-S6 mutants to 1,4-dihydropyridine analogs. Eur. J. Pharmacol. 602, 255-261. https://doi.org/10.1016/j.ejphar.2008.11.051
  10. Jiang, C. C., Chen, L. H., Gillespie, S., Kiejda, K. A., Mhaidat, N., Wang, Y. F., Thorne, R., Zhang, X. D. and Hersey, P. (2007) Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response. Cancer Res. 67, 5880-5888. https://doi.org/10.1158/0008-5472.CAN-07-0213
  11. Jin, C. Y., Moon, D. O., Lee, J. D., Heo, M. S., Choi, Y. H., Lee, C. M., Park, Y. M. and Kim, G. Y. (2007) Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis through downregulation of ERK and Akt in lung adenocarcinoma A549 cells. Carcinogenesis 28, 1058-1066.
  12. Johnstone, R. W., Frew, A. J. and Smyth, M. J. (2008) The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat. Rev. Cancer 8, 782-798. https://doi.org/10.1038/nrc2465
  13. Jouan-Lanhouet, S., Arshad, M. I., Piquet-Pellorce, C., Martin-Chouly, C., Le Moigne-Muller, G., Van Herreweghe, F., Takahashi, N., Sergent, O., Lagadic-Gossmann, D., Vandenabeele, P., Samson, M. and Dimanche-Boitrel, M. T. (2012) TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation. Cell Death Differ. 19, 2003-2014. https://doi.org/10.1038/cdd.2012.90
  14. Kaddour-Djebbar, I., Lakshmikanthan, V., Shirley, R. B., Ma, Y., Lewis, R. W. and Kumar, M.V. (2006) Therapeutic advantage of combining calcium channel blockers and TRAIL in prostate cancer. Mol. Cancer Ther. 5, 1958-1966. https://doi.org/10.1158/1535-7163.MCT-06-0011
  15. Kanwar, J. R., Kamalapuram, S. K. and Kanwar, R. K. (2011) Targeting survivin in cancer: the cell-signalling perspective. Drug Discov. Today 16, 485-494. https://doi.org/10.1016/j.drudis.2011.04.001
  16. Kawasaki, H., Toyoda, M., Shinohara, H., Okuda, J., Watanabe, I., Yamamoto, T., Tanaka, K., Tenjo, T. and Tanigawa, N. (2001) Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer 91, 2026-2032. https://doi.org/10.1002/1097-0142(20010601)91:11<2026::AID-CNCR1228>3.0.CO;2-E
  17. Kim, I. K., Chung, C. W., Woo, H. N., Hong, G. S., Nagata, S. and Jung, Y. K. (2000) Reconstitution of caspase-8 sensitizes JB6 cells to TRAIL. Biochem. Biophys. Res. Commun. 277, 311-316. https://doi.org/10.1006/bbrc.2000.3673
  18. Kim, S., Kang, J., Qiao, J., Thomas, R. P., Evers, B. M. and Chung, D. H. (2004) Phosphatidylinositol 3-kinase inhibition down-regulates survivin and facilitates TRAIL-mediated apoptosis in neuroblastomas. J. Pediatr. Surg. 39, 516-521. https://doi.org/10.1016/j.jpedsurg.2003.12.008
  19. Kim, Y. and Seol, D. W. (2003) TRAIL, a mighty apoptosis inducer. Mol. Cells 15, 283-293.
  20. Kwok, T. C., Ricker, N., Fraser, R., Chan, A. W., Burns, A., Stanley, E. F., McCourt, P., Cutler, S. R. and Roy, P. J. (2006) A small-molecule screen in C. elegans yields a new calcium channel antagonist. Nature 441, 91-95. https://doi.org/10.1038/nature04657
  21. Lamy, V., Bousserouel, S., Gosse, F., Minker, C., Lobstein, A. and Raul, F. (2011) Lupulone triggers p38 MAPK-controlled activation of p53 and of the TRAIL receptor apoptotic pathway in human colon cancer-derived metastatic cells. Oncol. Rep. 26, 109-114.
  22. Li, S.S., Yang, S., Wang, S., Yang, X. M., Tang, Q. L. and Wang, S. H. (2011) Latent membrane protein 1 mediates the resistance of nasopharyngeal carcinoma cells to TRAIL-induced apoptosis by activation of the PI3K/Akt signaling pathway. Oncol. Rep. 26, 1573-1579.
  23. Lu, M., Strohecker, A., Chen, F., Kwan, T., Bosman, J., Jordan, V. C. and Cryns, V. L. (2008) Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels. Clin. Cancer Res. 14, 3168-3176. https://doi.org/10.1158/1078-0432.CCR-07-4362
  24. Mahalingam, D., Szegezdi, E., Keane, M., de Jong, S. and Samali A. (2009) TRAIL receptor signalling and modulation: Are we on the right TRAIL? Cancer Treat Rev. 35, 280-288. https://doi.org/10.1016/j.ctrv.2008.11.006
  25. Oh, B., Park, S., Pak, J. H. and Kim, I. (2012) Downregulation of Mcl-1 by daunorubicin pretreatment reverses resistance of breast cancer cells to TNF-related apoptosis-inducing ligand. Biochem. Biophys. Res. Commun. 422, 42-47. https://doi.org/10.1016/j.bbrc.2012.04.093
  26. Okamoto, K., Okamoto, I., Okamoto, W., Tanaka, K., Takezawa, K., Kuwata, K., Yamaguchi, H., Nishio, K. and Nakagawa, K. (2010) Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations. Cancer Res. 70, 10402-10410. https://doi.org/10.1158/0008-5472.CAN-10-2438
  27. Ortiz, J. and Chou, L. L. (2012) Calcium up-regulated survivin expression and associated osteogenesis of normal human osteoblasts. J. Biomed. Mater. Res. 100, 1770-1776.
  28. Park, S. J., Park, S. H., Kim, J., Kim, J. H., Park, S. J., Hwang, J. J., Jin D.H., Jeong S., Lee S.J., Kim J.C., Kim I. and Cho D.H. (2012) Carnitine sensitizes TRAIL-resistant cancer cells to TRAIL-induced apoptotic cell death through the up-regulation of Bax. Biochem. Biophys. Res. Commun. 428, 185-190. https://doi.org/10.1016/j.bbrc.2012.10.038
  29. Pennati, M., Colella, G., Folini, M., Citti, L., Daidone, M. G. and Zaffaroni, N. (2002) Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. J. Clin. Invest. 109, 285-286. https://doi.org/10.1172/JCI0214891
  30. Raviv, Z., Zilberberg, A., Cohen, S., Reischer-Pelech, D., Horrix, C., Berger, M. R., Rosin-Arbesfeld R. and Flescher E. (2011) Methyl jasmonate down-regulates survivin expression and sensitizes colon carcinoma cells towards TRAIL-induced cytotoxicity. Br. J. Pharmacol. 164, 1433-1444. https://doi.org/10.1111/j.1476-5381.2011.01419.x
  31. Ryan, B. M., O'Donovan, N. and Duffy, M. J. (2009) Survivin: a new target for anti-cancer therapy. Cancer Treat. Rev. 35, 553-562. https://doi.org/10.1016/j.ctrv.2009.05.003
  32. Stout, R. F. Jr. and Parpura, V. (2011) Voltage-gated calcium channel types in cultured C. elegans CEPsh glial cells. Cell Calcium 50, 98-108. https://doi.org/10.1016/j.ceca.2011.05.016
  33. Sung, E. S., Kim, A., Park, J. S., Chung, J., Kwon, M. H. and Kim Y. S. (2010) Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells. Apoptosis 10, 1256-1269.
  34. Sung, E. S., Park, K. J., Choi, H. J., Kim, C. H. and Kim, Y. S. (2012) The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells. Exp. Cell Res. 318, 1564-1576. https://doi.org/10.1016/j.yexcr.2012.04.003
  35. Tamm, I., Wang, Y., Sausville, E., Scudiero, D. A., Vigna, N., Oltersdorf, T. and Reed, J. C. (1998) IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 58, 5315-5320.
  36. Vader, G., Kauw, J. J., Medema, R. H. and Lens, S. M. (2006) Survivin mediates targeting of the chromosomal passenger complex to the centromere and midbody. EMBO Rep. 7, 85-92. https://doi.org/10.1038/sj.embor.7400562
  37. van Geelen, C. M., Pennarun, B., Le, P.T., de Vries, E. G. and de Jong, S. (2011) Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5. BMC Cancer 11, 39. https://doi.org/10.1186/1471-2407-11-39
  38. Zhang, X., Inukai, T., Akahane, K., Hirose, K., Kuroda, I., Honna, H., Goi, K., Kagami, K., Tauchi, T., Yagita, H. and Sugita, K. (2011) Endoplasmic reticulum stress inducers, but not imatinib, sensitize Philadelphia chromosome-positive leukemia cells to TRAIL-mediated apoptosis. Leuk. Res. 35, 940-949. https://doi.org/10.1016/j.leukres.2011.03.016

Cited by

  1. Fluorescein Hydrazones as Novel Nonintercalative Topoisomerase Catalytic Inhibitors with Low DNA Toxicity vol.57, pp.21, 2014, https://doi.org/10.1021/jm501263m
  2. Discovery of dihydroxylated 2,4-diphenyl-6-thiophen-2-yl-pyridine as a non-intercalative DNA-binding topoisomerase II-specific catalytic inhibitor vol.80, 2014, https://doi.org/10.1016/j.ejmech.2014.04.066
  3. Caenorhabditis elegans as a powerful alternative model organism to promote research in genetic toxicology and biomedicine vol.91, pp.5, 2017, https://doi.org/10.1007/s00204-017-1944-7
  4. Association of survivin splice variants with prognosis and treatment of breast cancer vol.5, pp.5, 2013, https://doi.org/10.5306/wjco.v5.i5.883
  5. Origanum majorana Ethanolic Extract Promotes Colorectal Cancer Cell Death by Triggering Abortive Autophagy and Activation of the Extrinsic Apoptotic Pathway vol.9, pp.None, 2013, https://doi.org/10.3389/fonc.2019.00795
  6. 3-Bromopyruvate potentiates TRAIL-induced apoptosis in human colon cancer cells through a reactive oxygen species- and caspase-dependent mitochondrial pathway vol.97, pp.12, 2019, https://doi.org/10.1139/cjpp-2019-0131
  7. YM155 sensitizes HeLa cells to TRAIL-mediated apoptosis via cFLIP and survivin downregulation vol.20, pp.4, 2020, https://doi.org/10.3892/ol.2020.11933
  8. TRAIL of Hope Meeting Resistance in Cancer vol.6, pp.12, 2013, https://doi.org/10.1016/j.trecan.2020.06.006